Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen

The ongoing Phase II study trying combinations backboned by telaprevir and experimental polymerase inhibitor VX-222 continues with two quad-treatment arms and a plan to drop interferon again in the first quarter.